Immunotherapy vs. Targeted Therapy: Which Patients Match Which Option?
Key Takeaways
- Immunotherapy helps the immune system recognize and attack cancer, while targeted therapy blocks specific changes that help cancer grow.
- Not every cancer responds to either treatment; tumor type, genetic markers, and disease stage matter.
- Biomarker testing often guides treatment selection and can help match the right patient to the right therapy.
- Side effects differ between the two approaches, so monitoring and follow-up are essential.
- Some patients receive one approach, while others may need a combination or a different treatment plan altogether.
Medically reviewed by the Acıbadem clinical team — June 13, 2026
Immunotherapy and targeted therapy are two major approaches in modern cancer care, but they work in different ways and suit different patient and tumor profiles. A careful diagnosis, including tumor testing and overall health review, helps doctors decide which option may offer the best balance of benefit and risk.
Overview
When a cancer diagnosis is on the table, one of the first questions patients and families ask is simple: what treatment is most likely to work for this specific cancer? For many tumors, the answer is no longer limited to surgery, chemotherapy, or radiation. Immunotherapy and targeted therapy have become important options, especially when doctors can identify features that make a tumor biologically vulnerable.
Although both treatments are considered modern and personalized, they are not interchangeable. Immunotherapy supports the body’s own defenses so they can better recognize cancer cells. Targeted therapy, by contrast, acts more like a precision tool, interfering with particular molecules or pathways that the cancer depends on for survival and growth.
The best choice is usually not based on the word “cancer” alone. It depends on the tumor’s origin, its molecular profile, whether it has spread, what previous treatments have been used, and the patient’s overall health. For international patients planning care abroad, these details are usually reviewed before travel or during the early stages of evaluation, so the treatment plan can be as coordinated as possible from the start.
How Immunotherapy Works
Immunotherapy is designed to help the immune system do what it was meant to do: identify abnormal cells and respond to them. Cancer can hide from immune surveillance or send signals that weaken immune activity. Certain immunotherapy drugs interrupt those signals, allowing immune cells to become more active against the tumor.
There are several types of immunotherapy, but checkpoint inhibitors are among the best known. These medicines remove “brakes” from immune cells, which may help the body mount a stronger anti-cancer response. Other forms of immunotherapy may stimulate immune cells more directly or help the immune system recognize cancer in a more targeted way.
Immunotherapy is often considered for cancers such as melanoma, lung cancer, kidney cancer, bladder cancer, some head and neck cancers, and certain blood cancers. However, whether it is suitable depends on the tumor’s characteristics, prior treatments, and the patient’s ability to tolerate immune-related side effects.
How Targeted Therapy Works
Targeted therapy focuses on specific biological features inside cancer cells or in the signals that support them. Many cancers are driven by mutations, overactive proteins, or growth pathways that can be identified through laboratory testing. Targeted drugs are designed to interfere with those exact mechanisms.
This approach is often described as precision medicine because it depends on finding the right target before treatment begins. For example, a tumor may carry a mutation that makes it more likely to respond to a particular drug class, while another tumor with the same organ of origin may not respond at all. That is why two people with the “same” cancer can receive very different treatments.
Targeted therapy is used in several cancers, including some breast cancers, lung cancers, colorectal cancers, melanoma, leukemia, lymphoma, and thyroid cancers. It may be used alone or combined with other treatments, depending on how the disease behaves and how quickly it needs to be controlled.
Who Matches Which Option?
The most important factor is the biology of the tumor. If testing shows that the cancer carries a mutation, fusion, receptor, or pathway known to respond to a targeted drug, targeted therapy may be a strong option. If the cancer has features suggesting it may be visible to the immune system, or if specific biomarkers indicate benefit, immunotherapy may be more appropriate.
Doctors also look at the cancer’s stage and pace. Some cancers need fast shrinkage, which may influence whether a targeted drug, immunotherapy, a combination, or another treatment should be used. Prior treatments matter too, because a cancer that has already become resistant to one therapy may still respond to another.
General health is just as important as tumor biology. Autoimmune diseases, organ function, infection risk, and previous treatment side effects may affect whether immunotherapy is safe. Similarly, other medical conditions or the need to take multiple medicines may influence which targeted therapy is best suited to a patient’s situation.
- Tumor mutation or biomarker testing supports treatment matching.
- Some cancers are more likely to respond to immunotherapy, others to targeted therapy.
- Past treatment response helps guide the next step.
- Overall health can make one option safer than another.
Biomarkers and Testing Before Treatment
In modern oncology, the decision between immunotherapy and targeted therapy often begins with testing. Pathology review confirms the cancer type, while molecular or biomarker tests look for clues such as genetic changes, protein expression, or immune-related markers. These results can transform treatment from a general approach into one tailored to the tumor’s behavior.
Common tests may include tissue biopsy analysis, molecular profiling, and sometimes blood-based testing. In certain cancers, the doctor may also recommend testing for markers that help predict whether the immune system is likely to respond to treatment. The exact tests depend on the diagnosis, and not every cancer needs the same workup.
For patients receiving care internationally, it is often useful to bring previous pathology reports, imaging studies, and laboratory results. This can reduce duplication and help the oncology team decide quickly whether more testing is needed before treatment starts.
Treatment Experience and Side Effects
Immunotherapy and targeted therapy both tend to be different from standard chemotherapy in how they are given and how they feel day to day. Some are taken as tablets, while others are given by infusion. The schedule depends on the medicine, the cancer type, and whether the treatment is being used alone or in combination.
Side effects are not the same for everyone, but there are broad patterns. Immunotherapy can sometimes cause the immune system to affect healthy organs, leading to inflammation in areas such as the skin, bowel, liver, lungs, or hormone glands. Targeted therapy may cause problems such as rash, diarrhea, high blood pressure, fatigue, or changes in liver tests, depending on the drug.
Because side effects can appear gradually or unexpectedly, regular follow-up is important. Patients are usually advised to report new symptoms early, even if they seem mild. Prompt evaluation can help doctors adjust treatment, provide supportive care, or decide whether a pause is necessary.
Prevention & Self-care
There is no way to prevent every cancer from developing, and no self-care measure can replace appropriate treatment. Still, patients can support their care by staying organized, reporting symptoms promptly, and keeping a clear list of medications, supplements, and allergies. This is especially helpful when treatment is being coordinated across countries or between multiple specialists.
Rest, hydration, balanced nutrition, and gentle activity, when approved by the care team, can help patients cope with treatment. It is also wise to ask the oncology team which symptoms should trigger a call right away, since the most important warnings vary depending on whether a patient is receiving immunotherapy, targeted therapy, or both.
Patients should avoid starting new over-the-counter products or herbal remedies without checking first, because some can interfere with treatment or affect the liver, kidneys, or immune system. If travel is involved, planning medication refills, follow-up imaging, and local support in advance can make recovery much smoother.
When to See a Doctor
Patients should speak with an oncologist whenever a new cancer diagnosis is made, when treatment is no longer working as expected, or when molecular testing may open the door to a more precise option. A specialist can explain whether immunotherapy, targeted therapy, a combination, or another approach is most appropriate for the specific situation.
During treatment, new or worsening symptoms should be reported promptly. This is especially important for fever, shortness of breath, persistent diarrhea, jaundice, chest pain, severe rash, confusion, or sudden fatigue. These symptoms do not always mean a serious problem, but they should be reviewed quickly so the care team can respond safely.
For international patients, a second opinion can be helpful when treatment plans are complex or when pathology and biomarker testing need expert review. Acibadem Health Point’s multidisciplinary specialists and JCI-accredited hospitals diagnose and treat these conditions for international patients, with care planning that can include remote review, travel coordination, and follow-up guidance after return home.
Frequently asked questions
What is the main difference between immunotherapy and targeted therapy?
Immunotherapy helps the immune system recognize and attack cancer cells. Targeted therapy blocks specific molecules or pathways that cancer cells use to grow and survive. The best option depends on the tumor’s biology and the patient’s overall condition.
How do doctors decide which treatment is right?
Doctors usually combine pathology results, biomarker testing, cancer stage, prior treatments, and general health to choose a plan. In some cases, testing clearly points to one option. In others, a combination or a different treatment may be better.
Can every cancer be treated with immunotherapy or targeted therapy?
No. These treatments work best for cancers with certain biological features, and some tumors do not have a matching marker or pathway. That is why testing is so important before treatment begins.
Are these treatments less toxic than chemotherapy?
They can be different, but not automatically easier. Some patients tolerate them well, while others develop side effects that need careful monitoring. The pattern of side effects depends on the specific drug and the person receiving it.
Can immunotherapy and targeted therapy be used together?
Yes, in some cancers and for some patients, doctors may combine them or sequence them with other treatments. Whether that makes sense depends on the cancer type, test results, and how the patient has responded before.
What should a patient bring to a second-opinion visit?
It helps to bring biopsy reports, pathology slides if available, imaging scans, lab results, and a list of past treatments. This gives the oncology team a clearer picture and can reduce delays in deciding the next step.
References
- National Cancer Institute
- American Cancer Society
- American Society of Clinical Oncology
- European Society for Medical Oncology
- World Health Organization
This article is for general information only and is not a substitute for professional medical advice. Please consult a qualified doctor about your individual situation.
